RELMADA THERAPEUTICS INC (RLMD)

Company Profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. The company is headquartered in Coral Gables, Florida and currently employs 14 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive and monotherapy treatment of major depressive disorder.

Company Info

RELMADA THERAPEUTICS INC

2222 Ponce De Leon Blvd. 3Rd Floor

Coral Gables FLORIDA 10022

P: 16468763459

CEO: Sergio Traversa

Employees: 14

Website: https://www.relmada.com/